MSF calls for halt to payments for pneumococcal vaccine

3 December 2019

French healthcare non-profit Médecins Sans Frontières (MSF) has called on Gavi, the Vaccine Alliance, to stop payments to pharma majors Pfizer (NYSE: PFE) and GlaxoSmithKline (LSE: GSK) for their pneumococcal vaccine.

Ahead of a board meeting of the Swiss non-profit in New Delhi, MSF has called for the remaining money in a special $262 million fund to instead be used to support the uptake of a more affordable pneumococcal vaccine currently under development.

The first alternative pneumococcal vaccine is expected to be available in the next few months, and is expected to be priced at about $6 per child to Gavi in certain countries.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK